Six months vs 12 months MOS for the 2nd line NSCLC study, adaptive immunity, immunosuppression, reactivating the immune system, and maintenance therapy. As KT says, perhaps PPHM has shared this info with big pharma under confidentiality agreements. This was also intimated to shareholders on the 7/16 cc. Is it hyperbole to compare PPHM's share price to buying Microsoft at $1.70/share?
